DEPARTAMENTO DE
MEDICAMENTOS
VETERINARIOS

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

TILMINJECT 300 MG/ML SOLUTION FOR INJECTION FOR CATTLE AND SHEEP

CORREO ELECTRÓNICO

mresvet@aemps.es

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0333/001/DC
Name, strength and pharmaceutical form	Tilminject 300 mg/ml solution for injection for cattle and sheep.
Applicant	Laboratorios Calier, S.A. Barcelonès, 26, Pla De Ramassar 08520 Les Franqueses del Vallès Barcelona (Spain)
Active substance(s)	Tilmicosin
ATC Vetcode	QJ01FA91
Target species	Cattle and sheep
Indication for use	**Cattle** Treatment of bovine respiratory disease associated with *Mannheimia haemolytica* and *Pasteurella multocida*. Treatment of interdigital necrobacillosis. **Sheep** Treatment of respiratory tract infections caused by *Mannheimia haemolytica* and *Pasteurella multocida*. Treatment of foot rot in sheep caused by *Dichelobacter nodosus* and *Fusobacterium necrophorum.* Treatment of acute ovine mastitis caused by *Staphylococcus aureus* and *Mycoplasma agalactiae*.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	21/10/2020
Date product first authorised in the ReferenceMemberState (MRP only)	N/A
Concerned Member States for original procedure	CY, HR, CZ, EL, DE, IT, PT, PL, RO

I. SCIENTIFIC OVERVIEW

***For public assessment reports for the first authorisation in a range**:*

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains tilmicosin and propylene glycol, phosporic acid concentrated and water for injections as excipients.

The container/closure system is an amber glass vials (Type II) of 100 ml and 250 ml sealed with a bromobutyl rubber stopper and flip-off aluminium capsules.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is tilmicosin, an established active substance described in the USP. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

Current shelf life after the first opening of the product (28 days) has been supported by relevant stability data in line with relevant European guidelines.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL) (*for pharmaceuticals only)*

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13 (1) and bioequivalence with the reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13 (1) and bioequivalence with the reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

Although this is a generic application according to Article 13 (1) and bioequivalence with the reference product has been demonstrated, the applicant has provided a brief user safety assessment broadly in accordance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the initial predicted environmental concentration in soil (intensive PECsoil, initial = 29.14 µg/kg for cattle [>2 years] and extensive PECsoil, initial = 20.9 µg/kg for Beef cattle) is less than 100 µg/kg.

PBT assessment

Although no phase II was needed, it was considered during the assessment that since it is known that Tilmicosin is persistent in soil the following sentence was added to the SPC: “Tilmicosin is persistent in soil”.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted because this application is for a generic product, submitted in accordance with Article 13(1) of Directive 2001/82/EC and bioequivalence with a reference product has been demonstrated.

MRLs

The active substance tilmicosin is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010.

MRLs are listed below:

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs (µg/kg)	Target tissues
Tilmicosin	Tilmicosin	All other food producing species except poultry	50 µg/kg	Muscle
			50 µg/kg	Fat
			1 000 µg/kg	Liver
			1 000 µg/kg	Kidney
			50 µg/kg	Milk

Withdrawal Periods

Based on the data provided, the following withdrawal periods are justified:

Cattle:
Meat and offal: 70 days
Milk: 36 days
If the product is administered to cows during the dry period or to pregnant dairy heifers, milk should not be used for human consumption until 36 days after calving.

Sheep:
Meat and offal: 42 days
Milk: 18 days
If the product is administered to ewes during the dry period or to pregnant ewes, milk should not be used for human consumption until 18 days after lambing.

IV. CLINICAL ASSESSMENT (EFFICACY)

This is a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC. As bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

As this was a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, pre-clinical studies are not required.

IV.B Clinical Studies

As this was a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, clinical studies are not required.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None